Browse by author
Lookup NU author(s): Emeritus Professor Philip Home,
Dr Simon Ashwell
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Insulin glargine is an innovative, long-acting human insulin analogue, whose prolonged mean activity profile has no pronounced peak. Accordingly, it mimics more closely the natural physiological profile of basal endogenous insulin secretion than do traditional extended-acting insulins such as NPH insulin. As would be expected for a more satisfactory basal insulin, clinical trials comparing insulin glargine with NPH insulin show less nocturnal hypoglycaemia, improved pre-breakfast blood glucose levels, or both. Furthermore, no substantive safety concerns have emerged for insulin glargine. Thus, insulin glargine represents the first major advance in the provision of basal insulin injection therapy for people with type 1 and type 2 diabetes for over 50 years. Copyright © 2002 John Wiley & Sons, Ltd.
Author(s): Home PD; Ashwell SG
Publication type: Article
Publication status: Published
Journal: Diabetes/Metabolism Research and Reviews
ISSN (print): 1520-7552
ISSN (electronic): 1520-7560
Publisher: John Wiley & Sons Ltd.
PubMed id: 12324987
Altmetrics provided by Altmetric